5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
February 2023 in “Global Journal of Reproductive Medicine” Medical treatments for benign prostatic hyperplasia mainly relieve symptoms, while surgery is more effective but not always suitable for elderly patients.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
December 2025 in “Journal of the European Academy of Dermatology and Venereology” 46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg is more effective than finasteride 1mg for treating male pattern baldness.
10 citations
,
October 2020 in “Microscopy and Microanalysis” Resveratrol helps prevent finasteride-induced damage in male rats, improving reproductive function.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
1 citations
,
September 2023 in “AACE clinical case reports” Testosterone pellets might work for transgender men's hormone therapy, but more research is needed.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
May 2003 in “Reactions Weekly” 3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
May 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Effective treatments for trichotillomania include cognitive-behavioral therapy, certain medications, and alternative support tools.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
10 citations
,
December 2009 in “Journal of the American Geriatrics Society” Older adults using diuretics should manage water intake carefully to avoid low sodium levels.
2 citations
,
January 2016 in “Andrology”
January 2025 in “Annals of Dermatology” Low-dose dutasteride effectively and safely promotes hair growth in men.
4 citations
,
May 2019 in “Asian Journal of Pharmaceutical Sciences” Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
6 citations
,
June 2014 in “PubMed” Combining TUSV with finasteride effectively treats recurrent hemospermia.
1 citations
,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
May 2025 in “Reactions Weekly”
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.